OREGON HEALTH & SCIENCE UNIVERSITY
Dual Kinase and LSD1 Inhibition in Acute Myeloid Leukemia
Dual Kinase and LSD1 Inhibition in Acute Myeloid Leukemia is a funding opportunity from OREGON HEALTH & SCIENCE UNIVERSITY, up to 493761, closing June 30, 2028.
Jun 30, 2028
(700d left)Overview
PROJECT SUMMARY/ABSTRACT Kinase inhibitor therapy has made a minimal impact on the clinical treatment of patients with Acute Myeloid Leukemia (AML). We have shown that inhibition of the epigenetic regulator lysine-specific demethylase 1 (LSD1) augments the efficacy of kinase inhibition in AML, including drugs…